Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.
Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, with news centered on its approved medicines, TTR franchise, clinical pipeline and financial performance. Company updates commonly address AMVUTTRA/vutrisiran and ONPATTRO/patisiran for transthyretin-mediated amyloidosis, GIVLAARI/givosiran for acute hepatic porphyria, OXLUMO/lumasiran for primary hyperoxaluria type 1, and partner-commercialized RNAi medicines.
Recurring developments include quarterly product revenue reports, guidance, clinical and real-world data for ATTR-CM and other cardiovascular programs, pipeline progress across cardio-metabolic disease, neuroscience and hematology, disease-awareness collaborations, and investor conference presentations. Alnylam also reports on its Alnylam 2030 strategy and commercialization of RNAi medicines in global markets.
Alnylam (Nasdaq: ALNY) and Inceptive announced a strategic AI collaboration to speed discovery of RNAi therapeutics. The alliance is valued at up to $2 billion, with $30 million in upfront cash and equity and additional preclinical, regulatory, and commercial milestone payments.
By integrating Inceptive’s generative AI foundation models with Alnylam’s RNAi platform and 20+ years of proprietary siRNA data, the partners aim to enhance siRNA design, prioritize top candidates, and support Alnylam’s Alnylam 2030 pipeline expansion strategy.
Alnylam (Nasdaq: ALNY) released its 2025 Corporate Responsibility Report outlining progress across six pillars: Patients, Science, Employees, Communities, Environment & Operations, and Governance & Integrity.
Highlights include a 2030 Scope 1–2 GHG reduction framework, expanded global patient access support, and a $2 million, two-year Alnylam Challengers philanthropy commitment.
Alnylam (Nasdaq: ALNY) reported new HELIOS-B Phase 3 analyses of vutrisiran in ATTR-CM at Heart Failure 2026. Vutrisiran reduced all-cause mortality and recurrent cardiovascular events in patients with atrial fibrillation and showed consistent benefit across low SBP, high comorbidity, women, and those on background therapies.
A pooled safety analysis over 25,000 patient-years of TTR-silencing RNAi therapies found low, placebo-comparable rates of vitamin A deficiency-related ocular events and no clinically meaningful vitamin A deficiency. The DemonsTTRate real-world study will follow >2,000 ATTR-CM patients for up to five years.
Alnylam (Nasdaq: ALNY) said management will present company overviews at two investor conferences: BofA Securities Healthcare on May 13, 2026 at 10:40 am PT (1:40 pm ET) in Las Vegas, and Goldman Sachs Annual Healthcare on June 9, 2026 at 11:20 am ET in Miami.
A live audio webcast will be available on the Investors section of the company website, with replays posted within 48 hours after each event.
Alnylam (NASDAQ: ALNY) will present new analyses of vutrisiran in ATTR-CM at Heart Failure 2026 (May 9–12, 2026) in Barcelona. Presentations include HELIOS-B subgroup pharmacodynamics, pooled safety analyses on vitamin A outcomes, and the design of the global DemonsTTRate observational study.
Alnylam (Nasdaq: ALNY) reported Q1 2026 consolidated total revenues of $1.167 billion and total net product revenues of $1.036 billion (121% growth vs Q1 2025). Total TTR net product revenues were $910 million (153% growth). The company reiterated 2026 guidance of $4.9–$5.3 billion total net product revenues.
Cash and marketable securities were $3.0 billion as of March 31, 2026; multiple late‑stage clinical readouts are expected in H2 2026.
Alnylam (Nasdaq: ALNY) will report first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, April 30, 2026, before U.S. markets open. Management will discuss Q1 results and expectations on a conference call at 8:30 am ET.
A live audio webcast will be available on the company Investors website and an archived webcast will post approximately two hours after the event.
Alnylam (Nasdaq: ALNY) presented ACC.26 data showing vutrisiran improves quality of life and clinical outcomes in ATTR-CM and real-world adherence is high. Vutrisiran reduced progression to advanced disease (8.0% vs 10.7% placebo) and lowered risk of death/CV events by up to 77% in subgroups. A pooled Phase 2 analysis found zilebesiran’s safety profile acceptable, supporting the ongoing ZENITH Phase 3 CVOT initiated September 2025.
Alnylam (Nasdaq: ALNY) announced partnerships to advance earlier diagnosis and coordinated care for transthyretin-mediated cardiomyopathy (ATTR-CM).
The company will partner with Viz.ai to deploy an FDA-cleared echocardiography AI (Us2.ai) and launch the multi-system AWARE study at five pilot health systems later this year. Alnylam also supports a three-year American Heart Association learning collaborative with a 10-site cohort. A webinar is scheduled today at 9:30 am ET, with an archived webcast available ~two hours after the event.
Alnylam (Nasdaq: ALNY) will webcast a TTR Investor Webinar on Tuesday, March 24, 2026 at 9:30 AM ET. The event marks one year since U.S. FDA approval of AMVUTTRA for ATTR-CM and will feature senior commercial and medical leaders. A replay will be available within 48 hours.